September 2011 in “Cancer” Men who start losing hair at 20 may have a higher chance of getting prostate cancer later.
October 2008 in “The Journal of Urology” Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.
38 citations,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
June 2023 in “Journal of multidisciplinary sciences (Online)” PCOS is linked to a higher risk of endometrial cancer but not ovarian or breast cancer, and more research is needed on its role in cancer development and treatment effects.
75 citations,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
3 citations,
January 2017 in “Revista chilena de nutrición” Certain natural compounds called terpenes may help prevent prostate cancer.
March 2024 in “PLoS medicine” Physical activity, height, and smoking affect prostate cancer risk.
June 2023 in “Journal of multidisciplinary sciences” PCOS may increase the risk of certain cancers.
March 2011 in “European Urology Supplements” The document concludes that a new biosensor can efficiently detect prostate cancer cells and that standardized referrals help find significant cancers effectively.
37 citations,
April 2008 in “The Cochrane library” 5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
29 citations,
July 2009 in “BJU international” Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
50 citations,
April 2010 in “Biology direct” Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.
9 citations,
November 2021 in “Infectious Agents and Cancer” Androgen deprivation therapy doesn't lower the risk of death from COVID-19 in prostate cancer patients.
2 citations,
January 2011 in “Clinical medicine insights” Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
October 2006 in “Clinical Cancer Research” Antioxidants can block the cancer-fighting effects of doxorubicin.
1 citations,
January 2022 in “European Journal of Pharmacology” Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.
12 citations,
October 2018 in “Aging male/The aging male” Higher BMI and lower testosterone are linked to more aggressive prostate cancer.
7 citations,
May 2016 in “SpringerPlus” Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.
8 citations,
July 2021 in “F1000Research” Plant-based compounds might be a promising alternative for prostate cancer treatment with fewer side effects.
57 citations,
April 2009 in “The Journal of Steroid Biochemistry and Molecular Biology” Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.
7 citations,
August 2019 in “Bioorganic & medicinal chemistry” Analog 23 is a promising compound for prostate cancer treatment.
54 citations,
November 2001 in “Urology” The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.
16 citations,
October 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.
15 citations,
January 2009 in “International Journal of Andrology” Liquorice may reduce testosterone and affect male reproductive organs, potentially helping treat conditions like prostate cancer.
13 citations,
February 2022 in “JAMA Dermatology” Spironolactone does not increase cancer risk and may lower prostate cancer risk, but more research is needed.
4 citations,
December 2013 in “Archivio italiano di urologia, andrologia” Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.
June 2017 in “Journal of The American Academy of Dermatology” Most men with lichen planopilaris had it confirmed by biopsy and often had thyroid issues, sexual dysfunction, or prostate cancer, hinting at a link with hormonal problems.
May 2011 in “Expert Review of Endocrinology & Metabolism” Breast cancer survivors may have a higher risk of falls, tamoxifen could prevent breast cancer and deaths, new guidelines urge caution with prostate cancer therapy, and early balding in men may indicate a higher prostate cancer risk.
17 citations,
August 2011 in “Current Medicinal Chemistry” New treatments for enlarged prostate are being developed, some of which may be more effective than current medications.
14 citations,
November 2006 in “Current Medicinal Chemistry” New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.